ECSP088079A - ORAL FORMULATIONS THAT INCLUDE ONDANSETRON AND A HIGHLY DOSED EDULCORANT - Google Patents

ORAL FORMULATIONS THAT INCLUDE ONDANSETRON AND A HIGHLY DOSED EDULCORANT

Info

Publication number
ECSP088079A
ECSP088079A EC2008008079A ECSP088079A ECSP088079A EC SP088079 A ECSP088079 A EC SP088079A EC 2008008079 A EC2008008079 A EC 2008008079A EC SP088079 A ECSP088079 A EC SP088079A EC SP088079 A ECSP088079 A EC SP088079A
Authority
EC
Ecuador
Prior art keywords
edulcorant
oral formulations
highly dosed
include ondansetron
ondansetron
Prior art date
Application number
EC2008008079A
Other languages
Spanish (es)
Inventor
Junior Dante Alario
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37604052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088079(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of ECSP088079A publication Critical patent/ECSP088079A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas de administración oral, caracterizadas por contener sales solubles de ondansetrón y edulcorantes con alto poder endulzante, en proporciones elevadas en relación con el ingrediente activo.The present invention provides oral administration pharmaceutical compositions, characterized in that they contain soluble salts of ondansetron and sweeteners with high sweetening power, in high proportions in relation to the active ingredient.

EC2008008079A 2005-07-05 2008-01-04 ORAL FORMULATIONS THAT INCLUDE ONDANSETRON AND A HIGHLY DOSED EDULCORANT ECSP088079A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0502736-5A BRPI0502736A (en) 2005-07-05 2005-07-05 oral formulations of masked residual flavor ondansetron

Publications (1)

Publication Number Publication Date
ECSP088079A true ECSP088079A (en) 2008-02-20

Family

ID=37604052

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008079A ECSP088079A (en) 2005-07-05 2008-01-04 ORAL FORMULATIONS THAT INCLUDE ONDANSETRON AND A HIGHLY DOSED EDULCORANT

Country Status (3)

Country Link
BR (1) BRPI0502736A (en)
EC (1) ECSP088079A (en)
WO (1) WO2007003020A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1401086B1 (en) * 2010-07-19 2013-07-12 Farmalip S R L SWEETENER.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109763A1 (en) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmaceutical salts
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions

Also Published As

Publication number Publication date
BRPI0502736A (en) 2007-02-27
WO2007003020A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
CL2011000589A1 (en) Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
MY157772A (en) Antibody formulation
CR20110110A (en) PHARMACEUTICAL COMPOSITION
EA201290984A1 (en) PHARMACEUTICAL PHARMACEUTICAL COMPOSITIONS, PREVENTING ABUSE
GT200800107A (en) ORAL FORMULATIONS THAT INCLUDE TIGECICLINE
NO20080220L (en) Formulations with high drug loading and dosage forms
AR080491A1 (en) ORAL FORMULATIONS AND LIPOFILIC SALTS OF METHYLNTREXONE
NO20075111L (en) Pharmaceutical composition
PH12012501522A1 (en) Oral care compositions
WO2010021607A3 (en) Pharmaceutical formulation
HN2003000206A (en) PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO
EA201170512A1 (en) COMPOSITION FOR ORAL ADMINISTRATION
TR200900878A2 (en) Pharmaceutical formulations combined in a single dosage form
NO20073026L (en) 2-Alkoxy-3,4,5-trihydroxyalkylamides, preparation and compositions thereof, and use thereof
IN2012DN00359A (en)
ECSP10010576A (en) ORAL AND INJECTABLE FORMULATIONS OF TETRACICLINE COMPOUNDS
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
TR200900879A2 (en) Pharmaceutical compositions in which the active ingredients are combined in a single dosage form
AR054595A1 (en) GUANFACINE PHARMACEUTICAL FORMULATIONS / COMPOSITIONS APPROPRIATE FOR DAILY ADMINISTRATION FORM IN A SINGLE DOSE
CO6321223A2 (en) SOLID PHARMACEUTICAL FORMULATION CONTAINING CYCLOSTAZOL
BRPI0506779A (en) Ice cream formulation and ice cream
TR200806300A2 (en) Solubility enhancing pharmaceutical formulation
WO2010029093A3 (en) Compositions for percutaneous administration
ECSP088079A (en) ORAL FORMULATIONS THAT INCLUDE ONDANSETRON AND A HIGHLY DOSED EDULCORANT
ITFI20080016A1 (en) PHARMACEUTICAL FORMULATIONS ORAL CONTAINING GLYCLAZIDE.